With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
With lung SBRT. French researchers milked the infamous STARS/ROSEL pooled data in a complicated cost-effectiveness analysis, proclaiming lung SBRT to be dominant over lobectomy (i.e., it both costs less and produces more quality-adjusted life years). | Paix, Radiother Oncol 2018